Manuel Litchman
President, CEO, Interim CFO & DirectorDr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio, Inc. since April 24, 2017 also serves as an Interim CFO since November 15, 2024 and served as Interim Chief Financial Officer since December 11, 2023. He serves as Director at Cascade Prodrug, Incorporated since August 2025. Dr. Litchman served as the Chief Executive Officer and President of Arvinas, Inc. since January 12, 2015 until February 2017. Prior to Arvinas, Dr. Litchman spent more than 18 years with Novartis Pharmaceuticals Corporation, serving in multiple positions of increasing responsibility, focusing on oncology. Dr. Litchman served as Senior Vice President and Executive Global Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration with the University of Pennsylvania investigating chimeric antigen receptor modified T cells (CAR Ts) directed against CD19 on B cell malignancies. Since August 2012, he has led the CTL019 program, a Phase 2 collaboration with the University of Pennsylvania that is investigating chimeric antigen receptor modified T cells (CARTs) directed against CD19 on B cell malignancies. Prior to the start of the CTL019 collaboration he served as Head of Oncology Business Development and Licensing and Vice President at Novartis. He served as Senior Vice President and Global Program Head at Novartis Pharmaceuticals. Dr. Litchman began his career in Clinical Research at Hoffmann-La Roche, then transitioned to Sandoz/Novartis, where he led global clinical development programs. He later moved to Ursus Capital, a biotechnology hedge fund, where he held the position of Senior Equity Analyst, before eventually returning to Novartis and directed oncology / immunology clinical research at Hoffmann-La Roche Inc. He served as a Director of Arvinas, Inc. Dr. Litchman earned BA from Princeton University and M.D. degree at Yale University School of Medicine and completed his internal medicine residency and his hematology-oncology fellowship at New York Presbyterian Hospital/Weill Cornell Medical Center.
Positions
- Company NameMustang Bio, Inc.Stock CodeMBIOPositionPresident, CEO, Interim CFO & DirectorColleagues
- MSMichael S. WeissExecutive Chairman
- PCPeter CarneyController & Interim Chief Accounting Officer
- GFGreg FurrowChief Quality Officer
- RMRobyn M. HunterCorporate Secretary
- NHNeil HerskowitzIndependent & Non-Executive Director
- AJAdam J. ChillIndependent Director
- LALindsay Allan RosenwaldNon-Executive Director
